期刊文献+

CD80 D86和CD17L基因联合表达增强细胞毒性T淋巴细胞杀伤活性的机制 被引量:2

Mechaaism of enhancement of the CTL activity in mice co-expressing CD80, CD6 and CD137L genes
原文传递
导出
摘要 目的探讨CD80、CD86和CD137L基因联合表达增强宿主细胞毒性T淋巴细胞(CTL)杀伤活性的机制。方法BALB/c小鼠随机分为5组,A组接种H22-Wt细胞,B组接种14_22.neo细胞,C组接种H22-CDS0/CD86细胞,D组接种H22-CD137L细胞,E组接种H22-CDS0/CD86/CD137L细胞。分别于第14、35、56和84天,每组每次随机选取2只小鼠处死取材。原位末端标记法(TUNEL)和DNA ladder法检测脾淋巴细胞凋亡。电泳迁移率法(EMSA)检测T细胞核因子KB(NF-KB)活性。结果TUNEL检测结果显示,接种后第14天,A、B组脾淋巴细胞即出现大量凋亡,D组凋亡虽然较A、B组明显减少,但仍远高于C、E组。随接种时间推移,C组脾淋巴细胞凋亡逐渐增多,而E组这一趋势不明显,至第84天,C组和E组的脾淋巴细胞凋亡指数分别为30.84-9.2和14.4±4.5。DNA ladder检测结果显示,接种后第14、35、56和84天,C组和E组均检测出典型阳性结果,其中以C组第35、56和84天凋亡最明显。EMSA检测结果显示,A、B组T细胞NF.KB活性很低,D组显著高于A、B组,C、E组则显著高于A、B和D组。随着接种时间推移,E组NF-KB活性一直维持较高水平,而C组呈现逐渐下降趋势,至第84天,C组和E组的T细胞NF-KB活性分别为14.01±1.04和41.16±5.78。结论1/22-CD80/CD86/CD137L^+变异株接种荷瘤鼠后,CD28信号和CD137信号的协同作用可显著增强活化T细胞NF-KB活性,这可能是CD80、CD86和CD137L基因联合表达显著增强宿主CTL杀伤活性的机制之一。 Objective To study the mechanism of enhancement of the CTL activity in mice coexpressing of CD80, CD86 and CD137L genes. Methods The mice were randomly divided into five groups, named A, B, C, D and E. The group A and B were control groups (CG). H22-BAL B/c HCC mouse model was established by subcutaneous injection with hepatocellular carcinoma cells of cell line H22- Wt (group A), H22-neo (group B), H22-CD80/CD86 (group C), H22-CD137L (group D) and H22- CD80/CD86/CD137L(group E), respectively. On the 14th, 35th, 56th and 84th day after the first inoculation of tumor cells, TUNEL staining and DNA ladder examination were used to detect apoptosis of splenic T lymphocytes in all groups at each post-inoculation time point. Electrophoretie mobility-shift assay (EMSA) method was used to detect the activity of nuclear factor κB (NF-κB) in splenic T lymphocytes in each group at each time point post-inoculation. Results Apoptosis was found in a great number of T lymphocytes in CG on the 14th day, much more than that in group C and E. The number of apoptotic T cells in group C had a significant difference compared with that in the group E from 14th to 84th day (P = 0. 003). DNA ladder analysis showed typical positive results in group C and E. The significant apoptosis fragments were found in group C on 21st, 35th and 84th days. NF-KB activity of T cells in groups C and E was remarkably higher than that of groups CG and D, with higher in group D than that of CG ( P =0. 002), and with no significant difference between group C and E on 14th day. The activity in group E was stable andremarkably higher than that of group C on 56th and 84th days after the first inoculation. Conclusion H22- CD80/CD86/CD137L induces higher NF-KB activity of the host T cells by synergistic action of CD28 and CD137, which may be one of the mechanisms of enhancement of the host CTL activity induced by coexpression of CD80, CD86 and CD137L genes.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2008年第9期654-658,共5页 Chinese Journal of Oncology
基金 国家自然科学基金资助项目(30271236) 江苏省卫生厅重点课题(K200411) 江苏省医学重点学科建设基金资助项目(135-10)
关键词 CD80 CD86 CD137L 肝细胞癌 核因子ΚB 凋亡 CD80 CD86 CD137L Hepatocellular carcinoma NF-κB Apoptosis
  • 相关文献

参考文献14

  • 1Melero I, Bach N, Hellstrom KE, et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CIY28 co-stimulatory pathway. Eur J Immunol, 1998, 28:1116-1121.
  • 2Guinn BA, DeBenedette MA, Watts TH, et al. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol, 1999, 162 : 5003- 5010.
  • 3李国强,印洁,王学浩,孙倍成,俞悦.CD80 CD86和CD137L基因联合表达对小鼠肝癌种植模型肿瘤免疫原性的影响[J].中华肿瘤杂志,2006,28(7):490-493. 被引量:4
  • 4李国强,王学浩,印洁,俞悦.同时表达4-1BBL B7.1及B7.2三个共刺激分子基因小鼠肝癌细胞系的建立和意义[J].中国肿瘤临床,2006,33(22):1261-1264. 被引量:3
  • 5Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are to previously activated splenic T cells and inhibit activation- induced cell death. J Immunol, 1997, 158:2600-2609.
  • 6张学光 朱剑昆.共刺激分子及其在免疫应答中的作用[A].朱迅主编.免疫学新进展[C].北京:人民卫生出版社,2002.426.
  • 7Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol, 1999, 162: 5037-5040.
  • 8Bernstein WB, Cox JH, Aronson N-E, et al. Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4 ( + ) T cells to HIV-infected persons. Clin Immunol, 2004, 111 : 262- 274.
  • 9Heyninck K, Kreike MM, Beyaert R. Structure-function analysis of the A20-binding inhibitor of NF-kappa B activation, ABIN-1. FEBS Lett, 2003, 536:135-140.
  • 10Nair A, Venkatraman M, Maliekal TT, et al. NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene, 2003, 22:50-58.

二级参考文献16

  • 1Tatsumi T,Takehara T,Katayama K,et al.Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma[J].Hepatology,1997,25 (5):1108 ~ 1114
  • 2Borriello F,Freeman GJ,Edelhoff S,et al.Characterization of the murine B7-1 genomic locus reveals an additional exon encoding an alternative cytoplasmic domain and a chromosomal location of chromosome 16,band B5[J].J Immunol,1994,153 (11):5038~5048
  • 3Borriello F,Oliveros J,Freeman GJ,et al.Differential expression of alternate mB7-2 transcripts[J].J Immunol,1995,155 (12):5490 ~5497
  • 4Freeman GJ,Gray GS,Gimmi CD,et al.Structure,expression,and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7[J].J Exp Med,1991,174(3):625 ~631
  • 5Kawashita Y,Ohtsura A,Kaneda Y,et al.Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radioation[J].Hum Gene Ther,1999,10(9):1509~1519
  • 6Melero I,Bach N,Hellstrom KE,et al.Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand:synergy with the CD28 co-stimulatory pathway[J].Eur J Immunol,1998,28(3):1116~1121
  • 7Guinn BA,DeBenedette MA,Watts TH,et al.4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine[J].J Immunol,1999,162(8):5003~5010
  • 8Bukczynski J,Wen T,Watts TH.Costimulation of human CD28-T cells by 4-1BB ligand[J].Eur J Immunol,2003,33(2):446~454
  • 9Kim YJ,Broxmeyer HE.Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8 (+) T cells[J].J Hematother Stem Cell Res,2001,10(4):441 ~449
  • 10Martin-Fontecha A,Cavallo F,Bellone M,et al.Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors[J].Eur J Immunol,1996,26(8):1851~1859

共引文献5

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部